Adoptive Cell Therapy Across Cancer Diagnoses
Status: Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 08 Jan 2020
Price : $35 *
At a glance
- Drugs Aldesleukin (Primary) ; Cyclophosphamide (Primary) ; Fludarabine (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary) ; Tumour infiltrating lymphocytes (Primary)
- Indications Cancer
- Focus Adverse reactions
- 05 Jan 2020 Planned End Date changed from 13 Mar 2020 to 6 Jun 2020.
- 05 Jan 2020 Status changed from recruiting to active, no longer recruiting.
- 31 Aug 2018 Biomarkers information updated